Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors

被引：0
作者：
Toshihiko Doi
Kenji Tamura
Yuko Tanabe
Kan Yonemori
Takayuki Yoshino
Nozomu Fuse
Makoto Kodaira
Hideaki Bando
Kazuo Noguchi
Takashi Shimamoto
Atsushi Ohtsu
机构：
[1] National Cancer Center Hospital East,Exploratory Oncology Research & Clinical Trial Center
[2] National Cancer Center Hospital,undefined
[3] National Cancer Center,undefined
[4] MSD K.K.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 76卷
关键词：
MK-2206; pan-AKT inhibitor; Pharmacokinetics; Phase I study; Skin toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：409 / 416
页数：7
相关论文
共 50 条
[31]   A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors [J].
Pearson, Andrew D. J. ;
Federico, Sara M. ;
Aerts, Isabelle ;
Hargrave, Darren R. ;
DuBois, Steven G. ;
Iannone, Robert ;
Geschwindt, Ryan D. ;
Wang, Ruixue ;
Haluska, Frank G. ;
Trippett, Tanya M. ;
Geoerger, Birgit .
ONCOTARGET, 2016, 7 (51) :84736-84747
[32]   A Phase I Study of the Pharmacokinetics and Safety of Ipatasertib, an Akt Inhibitor in Chinese Patients With Locally Advanced or Metastatic Solid Tumors [J].
Zhang, Jian ;
Liu, Rujiao ;
Sutaria, Dhruvit ;
Sane, Rucha ;
Fan, Minhao ;
Wang, Rui ;
Song, Grace ;
Chen, Kui ;
Arzumanova, Ksenia ;
Hu, Xichun .
CLINICAL THERAPEUTICS, 2025, 47 (02) :128-134
[33]   Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies [J].
Deenen, Maarten J. ;
Klumpen, Heinz-Josef ;
Richel, Dick J. ;
Sparidans, Rolf W. ;
Weterman, Mariette J. ;
Beijnen, Jos H. ;
Schellens, Jan H. M. ;
Wilmink, Johanna W. .
INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) :1557-1565
[34]   Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies [J].
Maarten J. Deenen ;
Heinz-Josef Klümpen ;
Dick J. Richel ;
Rolf W. Sparidans ;
Mariette J. Weterman ;
Jos H. Beijnen ;
Jan H. M. Schellens ;
Johanna W. Wilmink .
Investigational New Drugs, 2012, 30 :1557-1565
[35]   Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005) [J].
Ramanathan, Ramesh K. ;
McDonough, Shannon L. ;
Kennecke, Hagen F. ;
Iqbal, Syma ;
Baranda, Joaquina C. ;
Seery, Tara E. ;
Lim, Howard J. ;
Hezel, Aram F. ;
Vaccaro, Gina M. ;
Blanke, Charles D. .
CANCER, 2015, 121 (13) :2193-2197
[36]   Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study [J].
Naito, Yoichi ;
Kuboki, Yasutoshi ;
Ikeda, Masafumi ;
Harano, Kenichi ;
Matsubara, Nobuaki ;
Toyoizumi, Shigeyuki ;
Mori, Yuko ;
Hori, Natsuki ;
Nagasawa, Takashi ;
Kogawa, Takahiro .
INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) :1568-1576
[37]   Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study [J].
Yoichi Naito ;
Yasutoshi Kuboki ;
Masafumi Ikeda ;
Kenichi Harano ;
Nobuaki Matsubara ;
Shigeyuki Toyoizumi ;
Yuko Mori ;
Natsuki Hori ;
Takashi Nagasawa ;
Takahiro Kogawa .
Investigational New Drugs, 2021, 39 :1568-1576
[38]   Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors [J].
Okamoto, Isamu ;
Doi, Toshihiko ;
Ohtsu, Atsushi ;
Miyazaki, Masaki ;
Tsuya, Asuka ;
Kurei, Katsutoshi ;
Kobayashi, Ken ;
Nakagawa, Kazuhiko .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (01) :17-23
[39]   Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors [J].
Nakamichi, Shinji ;
Nokihara, Hiroshi ;
Yamamoto, Noboru ;
Yamada, Yasuhide ;
Fujiwara, Yutaka ;
Tamura, Yosuke ;
Wakui, Hiroshi ;
Honda, Kazunori ;
Mizugaki, Hidenori ;
Kitazono, Satoru ;
Tanabe, Yuko ;
Asahina, Hajime ;
Yamazaki, Naoya ;
Suzuki, Shigenobu ;
Matsuoka, Mieko ;
Ogita, Yoshitaka ;
Tamura, Tomohide .
INVESTIGATIONAL NEW DRUGS, 2015, 33 (03) :641-651
[40]   Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079) [J].
B. B. Y. Ma ;
B. C. Goh ;
W. T. Lim ;
E. P. Hui ;
E. H. Tan ;
G. de Lima Lopes ;
K. W. Lo ;
L. Li ;
H. Loong ;
N. R. Foster ;
C. Erlichman ;
A. D. King ;
M. K. M. Kam ;
S. F. Leung ;
K. C. Chan ;
A. T. C. Chan .
Investigational New Drugs, 2015, 33 :985-991
12345